www.fdanews.com/articles/69686-astrazeneca-says-europe-backs-symbicort-patent
AstraZeneca Says Europe Backs Symbicort Patent
March 10, 2005
The European Patent Office has ruled the combination patent on AstraZeneca's asthma drug Symbicort is still valid, despite challenges from several generic manufacturers, the Anglo-Swedish group says. The patent on the inhaled treatment, which is a mixture of two medicines, expires in 2012 in Europe, with supplementary extensions to 2015 applicable in some countries.